• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

表皮生长因子受体突变的非小细胞肺癌中酪氨酸激酶抑制剂的研究趋势：一项文献计量分析

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis.

作者信息

Chang Xiaoyan, Wang Chenghao, Zhang Linyou

机构信息

Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.

出版信息

Drug Des Devel Ther. 2025 Mar 11;19:1703-1719. doi: 10.2147/DDDT.S510031. eCollection 2025.

DOI:10.2147/DDDT.S510031
PMID:40093643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11910061/
Abstract

BACKGROUND

This study seeks to identify research trends and hotspots concerning tyrosine kinase inhibitors (TKIs) for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) through a comprehensive bibliometric analysis.

METHODS

Publications on TKIs and EGFR-mutated NSCLC from 2006 to 2024 were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to visualize collaboration, keyword co-occurrences, and research trends.

RESULTS

A total of 962 articles were analyzed, authored by 7,458 researchers from 5,401 institutions across 208 countries. Wu Yi-Long was identified as the most prolific author, contributing 30 publications. AstraZeneca emerged as the industrial leader with 103 articles, while the New England Journal of Medicine was recognized as the primary journal with the highest total link strength. Keyword co-occurrence analysis revealed significant research topics including "gefitinib", "chemotherapy", "open label", and "erlotinib." Moreover, keyword burst analysis indicated notable periods of increased research focus on topics such as "osimertinib" and "liquid biopsy", suggesting emerging trends and current hotspots in the treatment of EGFR-mutated NSCLC.

CONCLUSION

This analysis highlights research trends on TKIs for EGFR-mutated NSCLC, emphasizing the importance of targeted therapies like gefitinib and osimertinib for future research and clinical practice enhancement.

摘要

背景

本研究旨在通过全面的文献计量分析，确定关于酪氨酸激酶抑制剂（TKIs）治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）的研究趋势和热点。

方法

使用VOSviewer、CiteSpace和R-bibliometrix对2006年至2024年期间关于TKIs和EGFR突变NSCLC的出版物进行分析，以可视化合作情况、关键词共现情况和研究趋势。

结果

共分析了962篇文章，这些文章由来自208个国家5401个机构的7458名研究人员撰写。吴一龙被确定为产量最高的作者，发表了30篇论文。阿斯利康以103篇文章成为行业领先者，而《新英格兰医学杂志》被认为是总链接强度最高的主要期刊。关键词共现分析揭示了重要的研究主题，包括“吉非替尼”、“化疗”、“开放标签”和“厄洛替尼”。此外，关键词突现分析表明，对“奥希替尼”和“液体活检”等主题的研究关注度显著增加的时期，这表明在EGFR突变NSCLC治疗中出现了新趋势和当前热点。

结论

本分析突出了EGFR突变NSCLC的TKIs研究趋势，强调了吉非替尼和奥希替尼等靶向治疗对未来研究和临床实践改进的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/083ea70e33ee/DDDT-19-1703-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/0a8e6928dd59/DDDT-19-1703-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/9a8703c16371/DDDT-19-1703-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/74ac067e1164/DDDT-19-1703-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/248d0183c3c5/DDDT-19-1703-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/8101c216d127/DDDT-19-1703-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/acf6cc330de4/DDDT-19-1703-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/6b176f8cae9e/DDDT-19-1703-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/083ea70e33ee/DDDT-19-1703-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/0a8e6928dd59/DDDT-19-1703-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/9a8703c16371/DDDT-19-1703-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/74ac067e1164/DDDT-19-1703-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/248d0183c3c5/DDDT-19-1703-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/8101c216d127/DDDT-19-1703-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/acf6cc330de4/DDDT-19-1703-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/6b176f8cae9e/DDDT-19-1703-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de60/11910061/083ea70e33ee/DDDT-19-1703-g0008.jpg

相似文献

1
Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis.表皮生长因子受体突变的非小细胞肺癌中酪氨酸激酶抑制剂的研究趋势：一项文献计量分析
Drug Des Devel Ther. 2025 Mar 11;19:1703-1719. doi: 10.2147/DDDT.S510031. eCollection 2025.
2
Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis.解析肺癌中表皮生长因子受体酪氨酸激酶抑制剂耐药的动态变化：文献计量分析的启示。
Drug Des Devel Ther. 2024 Sep 26;18:4327-4343. doi: 10.2147/DDDT.S478910. eCollection 2024.
3
A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.非小细胞肺癌中表皮生长因子受体抑制剂耐药性的研究动态的可视化分析。
Drug Des Devel Ther. 2024 Jun 26;18:2571-2591. doi: 10.2147/DDDT.S465238. eCollection 2024.
4
Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment.表皮生长因子受体（EGFR）突变的非小细胞肺癌靶向治疗的荟萃分析：奥希替尼、厄洛替尼和吉非替尼作为一线治疗的疗效和安全性
Am J Clin Oncol. 2025 Jan 1;48(1):44-54. doi: 10.1097/COC.0000000000001138. Epub 2024 Sep 11.
5
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.日本未经治疗的晚期 EGFR 突变型非小细胞肺癌一线奥希替尼和其他 EGFR 酪氨酸激酶抑制剂对总生存期的影响：来自 TREAD 项目 01 的更新数据。
Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20.
6
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring Class 3 Mutations.表皮生长因子受体酪氨酸激酶抑制剂在携带3类突变的非小细胞肺癌中的临床及临床前活性
JCO Precis Oncol. 2024 Dec;8:e2400240. doi: 10.1200/PO.24.00240. Epub 2024 Dec 5.
7
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
8
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?对于具有EGFR突变的非小细胞肺癌患者，应推荐哪种酪氨酸激酶抑制剂作为初始治疗？
Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Epub 2014 Jun 24.
9
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
10
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer.ONO-7475，一种新型的 AXL 抑制剂，抑制了 - 突变非小细胞肺癌对初始 EGFR-TKI 治疗的适应性耐药。
Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17.

本文引用的文献

1
In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.深入探讨 TKI 联合放疗治疗 EGFR 突变型肺腺癌伴脑转移患者的焦点问题：基于文献计量学、荟萃分析和真实世界观察数据的系统分析。
BMC Cancer. 2024 Oct 23;24(1):1305. doi: 10.1186/s12885-024-13071-2.
2
The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature.精准肿瘤学中酪氨酸激酶抑制剂的药物基因组学现状：文献计量分析
Pharmaceutics. 2024 Jan 25;16(2):167. doi: 10.3390/pharmaceutics16020167.
3
A revisit to the specification of sub-datasets and corresponding coverage timespans when using Web of Science Core Collection.
重新审视使用《科学网核心合集》时子数据集的规范及相应的覆盖时间跨度。
Heliyon. 2023 Nov 2;9(11):e21527. doi: 10.1016/j.heliyon.2023.e21527. eCollection 2023 Nov.
4
Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.酪氨酸激酶抑制剂治疗转移性肾细胞癌的比较安全性：一项系统评价和网状Meta分析
Front Pharmacol. 2023 Sep 7;14:1223929. doi: 10.3389/fphar.2023.1223929. eCollection 2023.
5
The Impact of Liquid Biopsies Positive for Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients.液体活检中突变阳性对非小细胞肺癌患者总生存期的影响。
Diagnostics (Basel). 2023 Jul 12;13(14):2347. doi: 10.3390/diagnostics13142347.
6
Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.伴有外显子 19 缺失和外显子 21 L858R EGFR 突变的肺腺癌非小细胞肺癌患者的临床病理特征、治疗和结局的差异。
BMJ Open Respir Res. 2023 Jun;10(1). doi: 10.1136/bmjresp-2022-001492.
7
Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis.非小细胞肺癌治疗中免疫检查点抑制剂的新兴趋势与研究重点：可视化与文献计量分析
Front Pharmacol. 2023 May 4;14:1140771. doi: 10.3389/fphar.2023.1140771. eCollection 2023.
8
Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.阿法替尼对比奥希替尼治疗非小细胞肺癌罕见 EGFR 突变患者的临床结局：一项汇总分析。
Oncologist. 2023 Jun 2;28(6):e397-e405. doi: 10.1093/oncolo/oyad111.
9
Machine learning in non-small cell lung cancer radiotherapy: A bibliometric analysis.非小细胞肺癌放疗中的机器学习：一项文献计量分析。
Front Oncol. 2023 Mar 17;13:1082423. doi: 10.3389/fonc.2023.1082423. eCollection 2023.
10
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis.全球肺癌免疫治疗的研究现状和趋势：文献计量分析。
Front Immunol. 2022 Dec 1;13:1032747. doi: 10.3389/fimmu.2022.1032747. eCollection 2022.